For patients with severe obesity (BMI 40 kg/m or 35 kg/m with comorbidities) who have not achieved adequate weight loss with non-surgical interventions, bariatric surgery may be considered following specialist assessment, as outlined in NICE CG189
Legitimate compounding continues where clinically justified, priced separately from FDA-approved brand products on its own structure
However, providers prescribe Ozempic for diabetes management and Wegovy for obesity
For more information about MEDVi's services, eligibility requirements, pricing, and state availability, visit www.medvi.org
DiBaise, M
this may helptreat and address several weight-related conditions, including heart conditions, diabetes and musculoskeletal issues